Post by Solomon Grey Capital

For two years, life sciences tools was the sub-sector pharma analysts apologised for owning. Merck KGaA's $11.3 billion all-cash bid for Bio-Techne ends that thesis. What just happened: → $73 per share in cash — 24% premium to last close, 36% to one-month VWAP → ~10x sales for a $1.2B revenue research-tools platform → Largest deal in Merck KGaA's history; EUR 140M synergies by year three → Bio-Techne up 21% on the day; sector index flat Why this is the signal: Kai Beckmann, CEO of Merck KGaA, told Reuters the timing was deliberate: "We have to look into valuations, and here of course timing matters" — a transaction at this price "wasn't possible two years ago." This is the fourth $10B+ healthcare deal in ten weeks (Sun Pharma/Organon, GSK/Nuvalent, AbbVie/Apogee, now Merck/Bio-Techne) — but it's the first one in research infrastructure rather than therapeutics. Anamaria Sudarov, head of healthcare investment banking at Wells Fargo, called it from the BIO Convention this week: the "$65 billion year-to-date M&A swamp" has left strategics with capital they are "eager to deploy" — and dual-track IPO/M&A processes are now the "bare minimum." ↓ Our view: this is not a green light to chase the biotech ETF. It is a green light to look at picks-and-shovels names left for dead — bioprocessing, reagents, cell and gene therapy workflow — where multiple compression has run further than fundamentals warrant. Full piece below. #SolomonGreyCapital #LifeSciences #MerckKGaA #BioTechne #PharmaMA